Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

Department of Neurology, Keio University School of Medicine, Tokyo, Japan. Electronic address: .
Journal of neuroimmunology (Impact Factor: 2.47). 04/2013; 258(1-2). DOI: 10.1016/j.jneuroim.2013.03.001
Source: PubMed


There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.

8 Reads